Spago Nanomedical AB (publ) (FRA:7UX)

Market Cap	8.31M -6.4%
Revenue (ttm)	343.91K -38.1%
Net Income	-2.37M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0052
Previous Close	0.0090
Day's Range	0.0052 - 0.0090
52-Week Range	0.0042 - 0.0276
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7UX

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.47 million, a decrease of -32.85% compared to the previous year's 6.66 million. Losses were -26.55 million, -18.32% less than in 2024.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 27, 2026

Data Sources Report a data error